In an increasingly uncertain market, where concentration risk looms large, savvy investors are seeking refuge in quality blue-chip stocks. With about 50% of the market's earnings stemming from the top ...

Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...

Don Nesbitt, senior portfolio manager at F/m Investments, joins BNN Bloomberg to share his Hot Picks in healthcare.

The Harbor Health Care ETF MEDI is now three years old and has performed so well that it has been rated five stars (the highest rating) within Morningstar's U.S. Fund Health category. The ...

AbbVie ABBV has been significantly expanding its presence in the oncology space. What started initially as a two-drug ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

AbbVie Inc. (NYSE: ABBV) garnered a ‘Buy’ rating from analyst Rajesh Kumar at HSBC, suggesting a robust upside potential for investors. The analyst set a price target of $265, indicating a notable ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of ...

HSBC analyst Rajesh Kumar upgraded AbbVie Inc. (NYSE: ABBV) from Hold to Buy and boosted the price target from $225 to $265.